Maintenance therapies for Hodgkin and non-Hodgkin lymphomas after autologous transplantation: a consensus project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT

Importance: Maintenance therapies are often considered as a therapeutic strategy in patients with lymphoma following autologous hematopoietic cell transplantation (auto-HCT) to mitigate the risk of disease relapse. With an evolving therapeutic landscape, where novel drugs are moving earlier in thera...

Full description

Saved in:
Bibliographic Details
Main Authors: Kanate, Abraham S. (Author) , Dreger, Peter (Author)
Format: Article (Journal)
Language:English
Published: February 28, 2019
In: JAMA oncology
Year: 2019, Volume: 5, Issue: 5, Pages: 715-722
ISSN:2374-2445
DOI:10.1001/jamaoncol.2018.6278
Online Access:Verlag, Pay-per-use, Volltext: https://doi.org/10.1001/jamaoncol.2018.6278
Verlag, Pay-per-use: https://jamanetwork.com/journals/jamaoncology/fullarticle/2726032
Get full text
Author Notes:Abraham S. Kanate, Ambuj Kumar, Peter Dreger, Martin Dreyling, Steven Le Gouill, Paolo Corradini, Chris Bredeson, Timothy S. Fenske, Sonali M. Smith, Anna Sureda, Alison Moskowitz, Jonathan W. Friedberg, David J. Inwards, Alex F. Herrera, Mohamed A. Kharfan-Dabaja, Nishitha Reddy, Silvia Montoto, Stephen P. Robinson, Syed A. Abutalib, Christian Gisselbrecht, Julie Vose, Ajay Gopal, Mazyar Shadman, Miguel-Angel Perales, Paul Carpenter, Bipin N. Savani, Mehdi Hamadani

MARC

LEADER 00000caa a2200000 c 4500
001 1677952172
003 DE-627
005 20230428021909.0
007 cr uuu---uuuuu
008 190930s2019 xx |||||o 00| ||eng c
024 7 |a 10.1001/jamaoncol.2018.6278  |2 doi 
035 |a (DE-627)1677952172 
035 |a (DE-599)KXP1677952172 
035 |a (OCoLC)1341244782 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Kanate, Abraham S.  |e VerfasserIn  |0 (DE-588)119605620X  |0 (DE-627)1677952601  |4 aut 
245 1 0 |a Maintenance therapies for Hodgkin and non-Hodgkin lymphomas after autologous transplantation  |b a consensus project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT  |c Abraham S. Kanate, Ambuj Kumar, Peter Dreger, Martin Dreyling, Steven Le Gouill, Paolo Corradini, Chris Bredeson, Timothy S. Fenske, Sonali M. Smith, Anna Sureda, Alison Moskowitz, Jonathan W. Friedberg, David J. Inwards, Alex F. Herrera, Mohamed A. Kharfan-Dabaja, Nishitha Reddy, Silvia Montoto, Stephen P. Robinson, Syed A. Abutalib, Christian Gisselbrecht, Julie Vose, Ajay Gopal, Mazyar Shadman, Miguel-Angel Perales, Paul Carpenter, Bipin N. Savani, Mehdi Hamadani 
264 1 |c February 28, 2019 
300 |a 8 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 30.09.2019 
520 |a Importance: Maintenance therapies are often considered as a therapeutic strategy in patients with lymphoma following autologous hematopoietic cell transplantation (auto-HCT) to mitigate the risk of disease relapse. With an evolving therapeutic landscape, where novel drugs are moving earlier in therapy lines, evidence relevant to contemporary practice is increasingly limited. The American Society for Blood and Marrow Transplantation (ASBMT), Center for International Blood and Marrow Transplant Research (CIBMTR), and European Society for Blood and Marrow Transplantation (EBMT) jointly convened an expert panel with diverse expertise and geographical representation to formulate consensus recommendations regarding the use of maintenance and/or consolidation therapies after auto-HCT in patients with lymphoma. Observations: The RAND-modified Delphi method was used to generate consensus statements where at least 75% vote in favor of a recommendation was considered as consensus. The process included 3 online surveys moderated by an independent methodological expert to ensure anonymity and an in-person meeting. The panel recommended restricting the histologic categories covered in this project to Hodgkin lymphoma (HL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), and follicular lymphoma. On completion of the voting process, the panel generated 22 consensus statements regarding post auto-HCT maintenance and/or consolidation therapies. The grade A recommendations included endorsement of: (1) brentuximab vedotin (BV) maintenance and/or consolidation in BV-naïve high-risk HL, (2) rituximab maintenance in MCL undergoing auto-HCT after first-line therapy, (3) rituximab maintenance in rituximab-naïve FL, and (4) No post auto-HCT maintenance was recommended in DLBCL. The panel also developed consensus statements for important real-world clinical scenarios, where randomized data are lacking to guide clinical practice. Conclusions and Relevance: In the absence of contemporary evidence-based data, the panel found RAND-modified Delphi methodology effective in providing a rigorous framework for developing consensus recommendations for post auto-HCT maintenance and/or consolidation therapies in lymphoma. 
700 1 |a Dreger, Peter  |e VerfasserIn  |0 (DE-588)1028891881  |0 (DE-627)732699894  |0 (DE-576)376320966  |4 aut 
773 0 8 |i Enthalten in  |t JAMA oncology  |d Chicago, Ill. : American Medical Association, 2015  |g 5(2019), 5, Seite 715-722  |h Online-Ressource  |w (DE-627)818494301  |w (DE-600)2810928-4  |w (DE-576)426501284  |x 2374-2445  |7 nnas  |a Maintenance therapies for Hodgkin and non-Hodgkin lymphomas after autologous transplantation a consensus project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT 
773 1 8 |g volume:5  |g year:2019  |g number:5  |g pages:715-722  |g extent:8  |a Maintenance therapies for Hodgkin and non-Hodgkin lymphomas after autologous transplantation a consensus project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT 
856 4 0 |u https://doi.org/10.1001/jamaoncol.2018.6278  |x Verlag  |x Resolving-System  |z Pay-per-use  |3 Volltext 
856 4 0 |u https://jamanetwork.com/journals/jamaoncology/fullarticle/2726032  |x Verlag  |z Pay-per-use 
951 |a AR 
992 |a 20190930 
993 |a Article 
994 |a 2019 
998 |g 1028891881  |a Dreger, Peter  |m 1028891881:Dreger, Peter  |d 910000  |d 910100  |e 910000PD1028891881  |e 910100PD1028891881  |k 0/910000/  |k 1/910000/910100/  |p 3 
999 |a KXP-PPN1677952172  |e 3519134527 
BIB |a Y 
SER |a journal 
JSO |a {"title":[{"title":"Maintenance therapies for Hodgkin and non-Hodgkin lymphomas after autologous transplantation","subtitle":"a consensus project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT","title_sort":"Maintenance therapies for Hodgkin and non-Hodgkin lymphomas after autologous transplantation"}],"language":["eng"],"person":[{"display":"Kanate, Abraham S.","role":"aut","given":"Abraham S.","family":"Kanate"},{"display":"Dreger, Peter","given":"Peter","role":"aut","family":"Dreger"}],"name":{"displayForm":["Abraham S. Kanate, Ambuj Kumar, Peter Dreger, Martin Dreyling, Steven Le Gouill, Paolo Corradini, Chris Bredeson, Timothy S. Fenske, Sonali M. Smith, Anna Sureda, Alison Moskowitz, Jonathan W. Friedberg, David J. Inwards, Alex F. Herrera, Mohamed A. Kharfan-Dabaja, Nishitha Reddy, Silvia Montoto, Stephen P. Robinson, Syed A. Abutalib, Christian Gisselbrecht, Julie Vose, Ajay Gopal, Mazyar Shadman, Miguel-Angel Perales, Paul Carpenter, Bipin N. Savani, Mehdi Hamadani"]},"physDesc":[{"extent":"8 S."}],"id":{"doi":["10.1001/jamaoncol.2018.6278"],"eki":["1677952172"]},"note":["Gesehen am 30.09.2019"],"relHost":[{"title":[{"title":"JAMA oncology","title_sort":"JAMA oncology"}],"language":["eng"],"part":{"year":"2019","text":"5(2019), 5, Seite 715-722","volume":"5","issue":"5","extent":"8","pages":"715-722"},"pubHistory":["1.2015 -"],"recId":"818494301","origin":[{"publisherPlace":"Chicago, Ill.","publisher":"American Medical Association","dateIssuedDisp":"2015-","dateIssuedKey":"2015"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"Maintenance therapies for Hodgkin and non-Hodgkin lymphomas after autologous transplantation a consensus project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMTJAMA oncology","physDesc":[{"extent":"Online-Ressource"}],"id":{"issn":["2374-2445"],"zdb":["2810928-4"],"eki":["818494301"]},"note":["Gesehen am 12.10.2017"],"corporate":[{"display":"American Medical Association","role":"isb"}]}],"origin":[{"dateIssuedKey":"2019","dateIssuedDisp":"February 28, 2019"}],"recId":"1677952172","type":{"media":"Online-Ressource","bibl":"article-journal"}} 
SRT |a KANATEABRAMAINTENANC2820